drugset / Trial / NCT07448116
Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, open-label Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of the anti-EGFR/c-Met bispecific antibody MCLA-129 in combination with Ensartinib hydrochloride in patients with advanced solid tumors.
Timeline
- Start
- 2026-01-31
- Primary completion
- 2029-02-01
- Completion
- 2029-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ensartinib | Small molecule | 150 mg | Oral |
| Subject | Ensartinib | Small molecule | 200 mg | Oral |
| Subject | PAMVATAMIG | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | PAMVATAMIG | Monoclonal antibody | 2000 mg | Intravenous |